Hyung-Keun Roh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hyung-Keun Roh has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Leif Bertilsson
Department of Laboratory Medicine, Division of Clinical Pharmacology
3 shared publicationsChang-Shin Park
Department of Pharmacology, College of Medicine, Inha University, Incheon, Korea
2 shared publicationsChang‐Shin Park
Department of Pharmacology,College of Medicine, Inha University, Incheon, and
1 shared publicationChul-Eung Kim
Department of Psychiatry, Inha University Hospital, Incheon, Korea
1 shared publicationDeok-In Kim
Department of Internal Medicine, Inha University Collage of Medicine, Incheon, Korea
1 shared publicationDon-Haeng Lee
Division of Gastroenterology, Inha University Hospital
1 shared publication
Latest Publications
- Open Access
- 1 January 2005
- Published by Korean Society for Clinical Pharmacology and Therapeutics in Journal of Korean Society for Clinical Pharmacology and Therapeutics
- Vol. 13 (1) , 92-97
A case of Oral Ethanol Treatment for Acute Ethylene Glycol Intoxication
Lee SH, et al. J Korean Soc Clin Pharmacol Ther. 2005 Jun;13(1):92-97. https://doi.org/10.12793/jkscpt.2005.13.1.92
- 1 January 2005
- Published by Korean Society for Clinical Pharmacology and Therapeutics in Journal of Korean Society for Clinical Pharmacology and Therapeutics
- Vol. 13 (1) , 92-97
Open AccessA case of Oral Ethanol Treatment for Acute Ethylene Glycol Intoxication
Lee SH, et al. J Korean Soc Clin Pharmacol Ther. 2005 Jun;13(1):92-97. https://doi.org/10.12793/jkscpt.2005.13.1.92
- Open Access
- 24 September 2004
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 95 (3) , 112-119
Omeprazole Treatment of Korean Patients: Effects on Gastric pH and Gastrin Release in Relation to CYP2C19 Geno- and Phenotypes
- 24 September 2004
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 95 (3) , 112-119
Open AccessOmeprazole Treatment of Korean Patients: Effects on Gastric pH and Gastrin Release in Relation to CYP2C19 Geno- and Phenotypes
- 1 November 2001
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 57 (9) , 671-675
Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients
Objective: Risperidone is known to be biotransformed to its active metabolite, 9-hydroxyrisperidone, by the polymorphic CYP2D6 in Caucasians. This study aimed to investigate the relationship between the CYP2D6*10 allele and the plasma levels of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. Methods: Eighty-two Korean schizophrenic patients in monotherapy with oral doses of risperidone from 1 mg/day to 8 mg/day (mean ±SD 4.3±1.9, median 4) participated in this study. Plasma concentrations of risperidone and 9-hydroxyrisperidone were analyzed using high-performance liquid chromatography. The CYP2D6*10 allele, which contains C188T mutation in exon 1, was identified using allele-specific polymerase chain reaction amplification. Results: Seventeen of 82 patients were homozygous for CYP2D6*1, 22 for *10, while the remaining 43 patients were heterozygous for these alleles. The plasma levels of risperidone and 9-hydroxyrisperidone ranged from 1.0 nM to 168 nM and 6.2 nM to 235 nM, respectively. The median concentrations/dose (C/Ds) (range) of risperidone in CYP2D6*1/*1, *1/*10, and *10/*10 groups were 1.7 (0.2–7.9), 2.6 (0.3–27.1), and 6.7 nM/mg (2.4–21.0), respectively. There was a statistically significant difference among the three genotypes (Kruskal-Wallis test, PP=0.54). The medians of the ratios between risperidone and 9-hydroxyrisperidone concentrations were 0.13 (0.01–0.93), 0.28 (0.01–2.77), and 0.46 nM/mg (0.05–1.28) in *1/*1, *1/*10, and *10/*10 genotypes, respectively, and they were significantly different (P=0.004). The active moieties (sum of the C/Ds of risperidone and 9-hydroxyrisperidone) were not significantly different between the genotypes (P=0.063). Conclusion: In Korean schizophrenic patients, the metabolism of risperidone is dependent on CYP2D6, and the CYP2D6*10 allele is important for the regulation of the activity of this enzyme. There were no significant differences in the plasma concentration of parent drug plus its active metabolite between the genotypes. This suggests that the clinical significance of this polymorphism is limited. Our study confirms previous studies on risperidone metabolism in Caucasians.
- 1 November 2001
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 57 (9) , 671-675
Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients
Objective: Risperidone is known to be biotransformed to its active metabolite, 9-hydroxyrisperidone, by the polymorphic CYP2D6 in Caucasians. This study aimed to investigate the relationship between the CYP2D6*10 allele and the plasma levels of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. Methods: Eighty-two Korean schizophrenic patients in monotherapy with oral doses of risperidone from 1 mg/day to 8 mg/day (mean ±SD 4.3±1.9, median 4) participated in this study. Plasma concentrations of risperidone and 9-hydroxyrisperidone were analyzed using high-performance liquid chromatography. The CYP2D6*10 allele, which contains C188T mutation in exon 1, was identified using allele-specific polymerase chain reaction amplification. Results: Seventeen of 82 patients were homozygous for CYP2D6*1, 22 for *10, while the remaining 43 patients were heterozygous for these alleles. The plasma levels of risperidone and 9-hydroxyrisperidone ranged from 1.0 nM to 168 nM and 6.2 nM to 235 nM, respectively. The median concentrations/dose (C/Ds) (range) of risperidone in CYP2D6*1/*1, *1/*10, and *10/*10 groups were 1.7 (0.2–7.9), 2.6 (0.3–27.1), and 6.7 nM/mg (2.4–21.0), respectively. There was a statistically significant difference among the three genotypes (Kruskal-Wallis test, PP=0.54). The medians of the ratios between risperidone and 9-hydroxyrisperidone concentrations were 0.13 (0.01–0.93), 0.28 (0.01–2.77), and 0.46 nM/mg (0.05–1.28) in *1/*1, *1/*10, and *10/*10 genotypes, respectively, and they were significantly different (P=0.004). The active moieties (sum of the C/Ds of risperidone and 9-hydroxyrisperidone) were not significantly different between the genotypes (P=0.063). Conclusion: In Korean schizophrenic patients, the metabolism of risperidone is dependent on CYP2D6, and the CYP2D6*10 allele is important for the regulation of the activity of this enzyme. There were no significant differences in the plasma concentration of parent drug plus its active metabolite between the genotypes. This suggests that the clinical significance of this polymorphism is limited. Our study confirms previous studies on risperidone metabolism in Caucasians.
- 1 September 2001
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 52 (3) , 265-271
Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients
Aims This study was carried out to evaluate the influence of CYP2D6 genotype on the steady state plasma concentrations of haloperidol and reduced haloperidol in Korean schizophrenic patients.Methods One hundred and twenty Korean schizophrenic patients treated with various, clinically determined, doses of haloperidol (range 3–60, median 20 mg day−1) during monotherapy were recruited. CYP2D6 genotypes were determined by analysis of the CYP2D6*10 allele using allele‐specific PCR and the CYP2D6*5 allele by long‐PCR. Steady state plasma concentrations of haloperidol and reduced haloperidol were analysed by h.p.l.c.Results Twenty‐three (19.2%), 60 (50.0%), 1 (0.8%), 33 (27.5%) and 3 patients (2.5%) possessed the CYP2D6 genotypes *1/*1, *1/*10, *1/*5, *10/*10 and *10/*5, respectively. The allele frequencies of CYP2D6*1, *10 and *5 were 44.6%, 53.8% and 1.7%, respectively. Significant relationships between dose and plasma concentrations of haloperidol (linear; r2 = 0.60, P < 0.0001) and reduced haloperidol (quadratic equation; r2 = 0.67) were observed. Overall, the concentrations normalized for dose (C/D) of haloperidol were significantly different between the CYP2D6*1/*1, *1/*10 and*10/*10 genotype groups (one‐way anova; P = 0.028). No significant differences between the genotype groups were found with respect to the C/D of reduced haloperidol (P = 0.755). However, in patients with daily doses less than 20 mg, significant differences in the C/D of haloperidol (P = 0.003), but not of reduced haloperidol, were found between the three major genotype groups. In patients with doses higher than 20 mg, no differences were found between the genotype groups for either haloperidol or reduced haloperidol. 68 patients (57%) used benztropine, an antimuscarinic agent. All four patients with a *5 allele (one together with *1 and three with *10) were found to use benztropine. The patients homozygous for the *1 allele seemed to need less benztropine than the patients with one or two mutated alleles (Fisher's exact test; P = 0.036).Conclusions The dose‐corrected steady state plasma concentrations of haloperidol, but not of reduced haloperidol, were significantly different between the CYP2D6*1/*1, *1/*10 and *10/*10 genotype groups when doses lower than 20 mg haloperidol were given. No differences were found at higher doses. These results suggest the involvement of CYP2D6 in the metabolism of haloperidol at low doses of haloperidol (< 20 mg daily), while another enzyme, probably CYP3A4, contributes at higher doses.
- 1 September 2001
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 52 (3) , 265-271
Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients
Aims This study was carried out to evaluate the influence of CYP2D6 genotype on the steady state plasma concentrations of haloperidol and reduced haloperidol in Korean schizophrenic patients.Methods One hundred and twenty Korean schizophrenic patients treated with various, clinically determined, doses of haloperidol (range 3–60, median 20 mg day−1) during monotherapy were recruited. CYP2D6 genotypes were determined by analysis of the CYP2D6*10 allele using allele‐specific PCR and the CYP2D6*5 allele by long‐PCR. Steady state plasma concentrations of haloperidol and reduced haloperidol were analysed by h.p.l.c.Results Twenty‐three (19.2%), 60 (50.0%), 1 (0.8%), 33 (27.5%) and 3 patients (2.5%) possessed the CYP2D6 genotypes *1/*1, *1/*10, *1/*5, *10/*10 and *10/*5, respectively. The allele frequencies of CYP2D6*1, *10 and *5 were 44.6%, 53.8% and 1.7%, respectively. Significant relationships between dose and plasma concentrations of haloperidol (linear; r2 = 0.60, P < 0.0001) and reduced haloperidol (quadratic equation; r2 = 0.67) were observed. Overall, the concentrations normalized for dose (C/D) of haloperidol were significantly different between the CYP2D6*1/*1, *1/*10 and*10/*10 genotype groups (one‐way anova; P = 0.028). No significant differences between the genotype groups were found with respect to the C/D of reduced haloperidol (P = 0.755). However, in patients with daily doses less than 20 mg, significant differences in the C/D of haloperidol (P = 0.003), but not of reduced haloperidol, were found between the three major genotype groups. In patients with doses higher than 20 mg, no differences were found between the genotype groups for either haloperidol or reduced haloperidol. 68 patients (57%) used benztropine, an antimuscarinic agent. All four patients with a *5 allele (one together with *1 and three with *10) were found to use benztropine. The patients homozygous for the *1 allele seemed to need less benztropine than the patients with one or two mutated alleles (Fisher's exact test; P = 0.036).Conclusions The dose‐corrected steady state plasma concentrations of haloperidol, but not of reduced haloperidol, were significantly different between the CYP2D6*1/*1, *1/*10 and *10/*10 genotype groups when doses lower than 20 mg haloperidol were given. No differences were found at higher doses. These results suggest the involvement of CYP2D6 in the metabolism of haloperidol at low doses of haloperidol (< 20 mg daily), while another enzyme, probably CYP3A4, contributes at higher doses.
- Open Access
- 1 January 2000
- Published by Korean Society for Clinical Pharmacology and Therapeutics in Journal of Korean Society for Clinical Pharmacology and Therapeutics
- Vol. 8 (1) , 144-150
Drug Interactions: Pharmacogenetic and Metabolic Aspects
Roh HK. J Korean Soc Clin Pharmacol Ther. 2000 Jun;8(1):144-150. https://doi.org/10.12793/jkscpt.2000.8.1.144
- 1 January 2000
- Published by Korean Society for Clinical Pharmacology and Therapeutics in Journal of Korean Society for Clinical Pharmacology and Therapeutics
- Vol. 8 (1) , 144-150
Open AccessDrug Interactions: Pharmacogenetic and Metabolic Aspects
Roh HK. J Korean Soc Clin Pharmacol Ther. 2000 Jun;8(1):144-150. https://doi.org/10.12793/jkscpt.2000.8.1.144